Beneficial Ownership Report · SCHEDULE 13G
Lantern Pharma Inc.
LTRNNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G
primary_doc.xml
Subject company
- Company
- Lantern Pharma Inc.
- Company CIK
- 0001763950
- Street
- 1920 McKinney Avenue, 7th Floor
- City
- Dallas
- State / country code
- TX
- Postal code
- 75201
Statement details
- Security class
- Common Stock, par value of $0.0001 per share
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(b)
Reporting person 1
- Name
- Armistice Capital, LLC
- Citizenship / organization
- DE
- Reporting person type
- IA · OO
- Aggregate amount owned
- 1,542,681.00
- Percent of class
- 9.99
- Sole voting power
- 0.00
- Shared voting power
- 1,542,681.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 1,542,681.00
- Aggregate excludes certain shares
- N
Reporting person 2
- Name
- Steven Boyd
- Citizenship / organization
- X1
- Reporting person type
- HC · IN
- Aggregate amount owned
- 1,542,681.00
- Percent of class
- 9.99
- Sole voting power
- 0.00
- Shared voting power
- 1,542,681.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 1,542,681.00
- Aggregate excludes certain shares
- N
Item 1
Issuer
Lantern Pharma Inc.
Principal executive office address
1920 McKinney Avenue, 7th Floor, Dallas, Texas 75201
Item 2
Citizenship
Armistice Capital, LLC - Delaware; Steven Boyd - United States of America
Filing person
Armistice Capital, LLC Steven Boyd Collectively, the "Reporting Persons"
Principal business or residence address
Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America Steven Boyd c/o Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America
Item 3
Not applicable indication
N
Type of filing person
IA · HC
Item 4
Percent of class
9.99%
Amount beneficially owned
1,542,681
Sole voting power
0
Shared voting power
1,542,681
Sole dispositive power
0
Shared dispositive power
1,542,681 Armistice Capital, LLC ("Armistice Capital") is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.
Item 5
Not applicable indication
Y
Item 6
Not applicable indication
N
Ownership on behalf of another person
The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Exhibits
JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: November 16, 2026 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd
Signature 1
- Reporting person
- Armistice Capital, LLC
- Signed
- /s/ Steven Boyd
- Title
- Steven Boyd - Managing Member
- Date
- 11/16/2026
Signature 2
- Reporting person
- Steven Boyd
- Signed
- /s/ Steven Boyd
- Title
- Steven Boyd
- Date
- 11/16/2026
Company context
We are an artificial intelligence (A.I.) focused company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Our development portfolio includes three clinical stage oncology focused product candidates and consists of small molecules that others have tried, but failed, to develop into an approved commercialized drug, as well as new compounds that we are developing with the assistance of our proprietary A.I. platform and our biomarker driven approach. Our A.I. platform, known as RADR®, currently includes more than 200 billion data points, and uses big data analytics (combining molecular data, drug efficacy data, data from historical studies, data from scientific literature, phenotypic data from trials and publications, and mechanistic pathway data) and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds. We believe our data-driven, genomically-targeted and biomarker-driven approach allows us to pursue a transformational drug development strategy that identifies, rescues or develops, and advances potential small molecule drug candidates at what we believe is a fraction of the time and cost associated with traditional cancer drug development. On average, our newly developed drug programs have been advanced from initial A.I. insights to first-in-human clinical t